Rebalancing the Immune System
NeoStem is collaborating with the University of California, San Francisco (UCSF) on our immunomodulation therapy platform targeting autoimmune disorders, which includes an FDA approved Phase 2 study in adolescents with type 1 diabetes. Through this program, NeoStem is pursuing the development of cell therapies using a person’s immune cells as a therapeutic product to treat disorders of the immune system.
Many immune-mediated diseases are a result of an imbalance in the immune system whereby inflammatory cells go unchecked. Therapy using T regulatory cells (Tregs) represents a novel approach to restoring immune balance by enhancing Treg cell number and function to inhibit pathogenic immune responses.
Through exclusive world-wide licenses to more than 30 issued patents and patent applications, we have secured the rights to a broad patent estate within the Treg field, covering natural Tregs (nTregs), induced Tregs (iTregs) and methods of treating or preventing certain conditions and/or diseases by use of Tregs. Both types of Tregs have been shown in pre-clinical studies to be important in modulating autoimmune and inflammatory diseases. nTregs have been evaluated by others in early phase human clinical trials and shown to be safe with suggestions of clinical benefit in graft-versus-host disease. Both nTregs and iTregs have demonstrated the ability to treat conditions like diabetes, inflammatory bowel disease and organ transplant tolerance in animal models of disease.
NeoStem’s Immune Modulation Program is establishing methods to isolate and expand human nTregs for large scale manufacturing to enable our planned clinical trials.